Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Dow
Merck
Johnson and Johnson
Boehringer Ingelheim

Last Updated: February 27, 2020

DrugPatentWatch Database Preview

FARYDAK Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Farydak patents expire, and when can generic versions of Farydak launch?

Farydak is a drug marketed by Secura and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and twelve patent family members in forty-seven countries.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the panobinostat lactate profile page.

US ANDA Litigation and Generic Entry Outlook for Farydak

Farydak was eligible for patent challenges on February 23, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 17, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for FARYDAK
Drug Prices for FARYDAK

See drug prices for FARYDAK

Generic Entry Opportunity Date for FARYDAK
Generic Entry Date for FARYDAK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FARYDAK

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of WashingtonPhase 2
National Cancer Institute (NCI)Phase 2
Novartis PharmaceuticalsPhase 2

See all FARYDAK clinical trials

Recent Litigation for FARYDAK

Identify potential future generic entrants

District Court Litigation
Case NameDate
Wyeth LLC v. Sun Pharmaceutical Industries, Inc.2016-12-23

See all FARYDAK litigation

Synonyms for FARYDAK
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(E)-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enehydroxamic acid
(E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide
(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indole-3-yl)ethyl]amino]methyl]phenyl]acrylamide
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
139304-EP2270008A1
139304-EP2292617A1
2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-
2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
404950-80-7
4CA-0964
9647FM7Y3Z
A25218
A8178
AB0007883
ABP000143
AC-28652
AC1OCFY8
ACN-025765
AJ-80437
AK-77283
AKOS005146046
AM808102
AOB87727
AS-17046
AX8223959
BC203264
BCP01816
BCP9000844
BCPP000187
BDBM198124
BDBM29589
BR-77283
BRD-K02130563-001-07-2
CCG-208762
CHEBI:85990
CHEBI:93774
CHEMBL483254
CS-0267
D10319
DB-025426
DB06603
DTXSID40193506
EX-8456
EX-A169
Faridak
Farydak (TN)
FPOHNWQLNRZRFC-ZHACJKMWSA-N
FT-0083488
GTPL7489
HY-10224
J-523585
KB-59423
LBH 589
LBH-589
LBH-589/Panobinostat /LBH589
LBH-589B
LBH58,9NVP-LBH589,Panobinostat
LBH589
LBH589 - Panobinostat
MLS006011216
MolPort-005-933-338
N-hydroxy-3 -[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide
NCGC00263117-07
NVP-LBH 589; Panobinostat
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat (LBH589)
Panobinostat (USAN/INN)
Panobinostat [USAN:INN]
Panobinostat;(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
Panobinostat(LBH589)
PubChem19147
QC-10419
RL03555
RT-014934
s1030
SB16464
SC-85907
SCHEMBL164801
SCHEMBL183197
SMR004702978
ST2402529
SW219369-1
UNII-9647FM7Y3Z
W-5406
W6096
ZINC22010649

US Patents and Regulatory Information for FARYDAK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for FARYDAK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1318980 C01318980/01 Switzerland   Start Trial PRODUCT NAME: PANOBINOSTAT; REGISTRATION NO/DATE: SWISSMEDIC 61878 23.12.2015
1318980 2015/066 Ireland   Start Trial PRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1023 20150828
1318980 1590070-7 Sweden   Start Trial PRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALTTHEREOF; REG. NO/DATE: EU/1/15/1023 20150901
1912640 C20160001 00181 Estonia   Start Trial PRODUCT NAME: PANOBINOSTAAT;REG NO/DATE: EU/1/15/1023 01.09.2015
1318980 92890 Luxembourg   Start Trial PRODUCT NAME: PANOBINSTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE , OU UN DERIVE DE CELUI-CI (FARYDAK); FIRST REGISTRATION: 20150901
1318980 CA 2015 00068 Denmark   Start Trial PRODUCT NAME: PANOBINOSTAT ELLER ET FARMACEUTISK SALT ELLER DERIVAT DERAF; REG. NO/DATE: EU/1/15/1023 20150901
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
Dow
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.